137 related articles for article (PubMed ID: 37561893)
21. Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors.
Ghobadian R; Esfandyari R; Nadri H; Moradi A; Mahdavi M; Akbarzadeh T; Khaleghzadeh-Ahangar H; Edraki N; Sharifzadeh M; Amini M
Mol Divers; 2020 Feb; 24(1):211-223. PubMed ID: 30927138
[TBL] [Abstract][Full Text] [Related]
22. Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer's Disease Mouse Model.
Spatz P; Steinmüller SAM; Tutov A; Poeta E; Morilleau A; Carles A; Deventer MH; Hofmann J; Stove CP; Monti B; Maurice T; Decker M
J Med Chem; 2023 May; 66(9):6414-6435. PubMed ID: 37127287
[TBL] [Abstract][Full Text] [Related]
23. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
24. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
26. Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.
Xu A; He F; Zhang X; Li X; Ran Y; Wei C; James Chou C; Zhang R; Wu J
Bioorg Chem; 2020 May; 98():103721. PubMed ID: 32193030
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Tseng HJ; Lin MH; Shiao YJ; Yang YC; Chu JC; Chen CY; Chen YY; Lin TE; Su CJ; Pan SL; Chen LC; Wang CY; Hsu KC; Huang WJ
Eur J Med Chem; 2020 Apr; 192():112193. PubMed ID: 32151835
[TBL] [Abstract][Full Text] [Related]
28. Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening.
Atatreh N; Al Rawashdah S; Al Neyadi SS; Abuhamdah SM; Ghattas MA
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1373-1379. PubMed ID: 31347933
[TBL] [Abstract][Full Text] [Related]
29. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
Makhaeva GF; Lushchekina SV; Boltneva NP; Serebryakova OG; Rudakova EV; Ustyugov AA; Bachurin SO; Shchepochkin AV; Chupakhin ON; Charushin VN; Richardson RJ
Bioorg Med Chem; 2017 Nov; 25(21):5981-5994. PubMed ID: 28986116
[TBL] [Abstract][Full Text] [Related]
30. Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies.
Mutahir S; Jończyk J; Bajda M; Khan IU; Khan MA; Ullah N; Ashraf M; Qurat-ul-Ain ; Riaz S; Hussain S; Yar M
Bioorg Chem; 2016 Feb; 64():13-20. PubMed ID: 26595185
[TBL] [Abstract][Full Text] [Related]
31. Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Riaz S; Khan IU; Bajda M; Ashraf M; Qurat-Ul-Ain ; Shaukat A; Rehman TU; Mutahir S; Hussain S; Mustafa G; Yar M
Bioorg Chem; 2015 Dec; 63():64-71. PubMed ID: 26451651
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
[TBL] [Abstract][Full Text] [Related]
33. Geissoschizoline, a promising alkaloid for Alzheimer's disease: Inhibition of human cholinesterases, anti-inflammatory effects and molecular docking.
Lima JA; R Costa TW; da Fonseca ACC; do Amaral RF; Nascimento MDDSB; Santos-Filho OA; de Miranda ALP; Ferreira Neto DC; Lima FRS; Hamerski L; Tinoco LW
Bioorg Chem; 2020 Nov; 104():104215. PubMed ID: 32920358
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of novel arylisoxazoles linked to tacrine moiety: in vitro and in vivo biological activities against Alzheimer's disease.
Rastegari A; Safavi M; Vafadarnejad F; Najafi Z; Hariri R; Bukhari SNA; Iraji A; Edraki N; Firuzi O; Saeedi M; Mahdavi M; Akbarzadeh T
Mol Divers; 2022 Feb; 26(1):409-428. PubMed ID: 34273065
[TBL] [Abstract][Full Text] [Related]
35. An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.
Rehman TU; Khan IU; Ashraf M; Tarazi H; Riaz S; Yar M
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220522
[TBL] [Abstract][Full Text] [Related]
36. Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.
Williams A; Zhou S; Zhan CG
Bioorg Med Chem Lett; 2019 Dec; 29(24):126754. PubMed ID: 31708262
[TBL] [Abstract][Full Text] [Related]
37. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
He F; Chou CJ; Scheiner M; Poeta E; Yuan Chen N; Gunesch S; Hoffmann M; Sotriffer C; Monti B; Maurice T; Decker M
J Med Chem; 2021 Apr; 64(7):3794-3812. PubMed ID: 33769811
[TBL] [Abstract][Full Text] [Related]
38. Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazoles.
Ozadali-Sari K; Tüylü Küçükkılınç T; Ayazgok B; Balkan A; Unsal-Tan O
Bioorg Chem; 2017 Jun; 72():208-214. PubMed ID: 28478328
[TBL] [Abstract][Full Text] [Related]
39. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T
Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890
[TBL] [Abstract][Full Text] [Related]
40. Conjugates of Tacrine and Salicylic Acid Derivatives as New Promising Multitarget Agents for Alzheimer's Disease.
Makhaeva GF; Kovaleva NV; Rudakova EV; Boltneva NP; Grishchenko MV; Lushchekina SV; Astakhova TY; Serebryakova OG; Timokhina EN; Zhilina EF; Shchegolkov EV; Ulitko MV; Radchenko EV; Palyulin VA; Burgart YV; Saloutin VI; Bachurin SO; Richardson RJ
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
